UroGen Pharma Ltd. fell 16.5% on Wednesday, November 4, 2026, on 2,897,400 shares, 2.8 times its average daily volume. Headlines around the move:
UroGen Pharma Ltd. (URGN:NASDAQ) closed at $25.32 on November 10, 2026, down 3.76% on the day. The stock trades 50.2% below its 52-week high of $50.81 and 53.5% above its 52-week low of $16.50. Over the past year, it gained 13.7%. UroGen Pharma Ltd. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, URGN closed higher on 121 days (48%). Its best day was August 5, 2026 (+16.31%) and its worst was November 4, 2026 (-16.45%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 2 times.
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies.
Find more stocks like URGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.